Literature DB >> 11015450

Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family.

J R Thomson1, R D Machado, M W Pauciulo, N V Morgan, M Humbert, G C Elliott, K Ward, M Yacoub, G Mikhail, P Rogers, J Newman, L Wheeler, T Higenbottam, J S Gibbs, J Egan, A Crozier, A Peacock, R Allcock, P Corris, J E Loyd, R C Trembath, W C Nichols.   

Abstract

BACKGROUND: Primary pulmonary hypertension (PPH), resulting from occlusion of small pulmonary arteries, is a devastating condition. Mutations of the bone morphogenetic protein receptor type II gene (BMPR2), a component of the transforming growth factor beta (TGF-beta) family which plays a key role in cell growth, have recently been identified as causing familial PPH. We have searched for BMPR2 gene mutations in sporadic PPH patients to determine whether the same genetic defect underlies the more common form of the disorder.
METHODS: We investigated 50 unrelated patients, with a clinical diagnosis of PPH and no identifiable family history of pulmonary hypertension, by direct sequencing of the entire coding region and intron/exon boundaries of the BMPR2 gene. DNA from available parent pairs (n=5) was used to assess the occurrence of spontaneous (de novo) mutations contributing to sporadic PPH.
RESULTS: We found a total of 11 different heterozygous germline mutations of the BMPR2 gene in 13 of the 50 PPH patients studied, including missense (n=3), nonsense (n=3), and frameshift (n=5) mutations each predicted to alter the cell signalling response to specific ligands. Parental analysis showed three occurrences of paternal transmission and two of de novo mutation of the BMPR2 gene in sporadic PPH.
CONCLUSION: The sporadic form of PPH is associated with germline mutations of the gene encoding the receptor protein BMPR-II in at least 26% of cases. A molecular classification of PPH, based upon the presence or absence of BMPR2 mutations, has important implications for patient management and screening of relatives.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11015450      PMCID: PMC1757155          DOI: 10.1136/jmg.37.10.741

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  20 in total

Review 1.  Role of transforming growth factor beta in human disease.

Authors:  G C Blobe; W P Schiemann; H F Lodish
Journal:  N Engl J Med       Date:  2000-05-04       Impact factor: 91.245

2.  Fine mapping of PPH1, a gene for familial primary pulmonary hypertension, to a 3-cM region on chromosome 2q33.

Authors:  Z Deng; F Haghighi; L Helleby; K Vanterpool; E M Horn; R J Barst; S E Hodge; J H Morse; J A Knowles
Journal:  Am J Respir Crit Care Med       Date:  2000-03       Impact factor: 21.405

3.  Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry.

Authors:  G G Pietra; W D Edwards; J M Kay; S Rich; J Kernis; B Schloo; S M Ayres; E H Bergofsky; B H Brundage; K M Detre
Journal:  Circulation       Date:  1989-11       Impact factor: 29.690

4.  The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension.

Authors:  S Rich; E Kaufmann; P S Levy
Journal:  N Engl J Med       Date:  1992-07-09       Impact factor: 91.245

5.  Familial primary pulmonary hypertension: clinical patterns.

Authors:  J E Loyd; R K Primm; J H Newman
Journal:  Am Rev Respir Dis       Date:  1984-01

6.  Clinical and pathologic manifestations of pulmonary vascular disease in the toxic oil syndrome.

Authors:  M A Gomez-Sanchez; C Saenz de la Calzada; C Gomez-Pajuelo; F J Martinez-Tello; M J Mestre de Juan; T N James
Journal:  J Am Coll Cardiol       Date:  1991-11-15       Impact factor: 24.094

7.  Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension.

Authors:  T W Higenbottam; D Spiegelhalter; J P Scott; V Fuster; A T Dinh-Xuan; N Caine; J Wallwork
Journal:  Br Heart J       Date:  1993-10

8.  Primary pulmonary hypertension. A national prospective study.

Authors:  S Rich; D R Dantzker; S M Ayres; E H Bergofsky; B H Brundage; K M Detre; A P Fishman; R M Goldring; B M Groves; S K Koerner
Journal:  Ann Intern Med       Date:  1987-08       Impact factor: 25.391

Review 9.  Genetic abnormalities in hereditary hemorrhagic telangiectasia.

Authors:  D A Marchuk
Journal:  Curr Opin Hematol       Date:  1998-09       Impact factor: 3.284

10.  Heterogeneity of pathologic lesions in familial primary pulmonary hypertension.

Authors:  J E Loyd; J B Atkinson; G G Pietra; R Virmani; J H Newman
Journal:  Am Rev Respir Dis       Date:  1988-10
View more
  163 in total

Review 1.  Pulmonary arterial hypertension: new ideas and perspectives.

Authors:  N Galiè; A Torbicki
Journal:  Heart       Date:  2001-04       Impact factor: 5.994

Review 2.  Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension.

Authors:  Ezequiel Balmori Melian; Karen L Goa
Journal:  Drugs       Date:  2002       Impact factor: 9.546

3.  Recommendations on the management of pulmonary hypertension in clinical practice.

Authors: 
Journal:  Heart       Date:  2001-09       Impact factor: 5.994

Review 4.  New insights into the pathogenesis and treatment of primary pulmonary hypertension.

Authors:  N Rudarakanchana; R C Trembath; N W Morrell
Journal:  Thorax       Date:  2001-11       Impact factor: 9.139

Review 5.  Pulmonary hypertension in the young.

Authors:  Sheila G Haworth
Journal:  Heart       Date:  2002-12       Impact factor: 5.994

Review 6.  Reactive oxygen and nitrogen species in pulmonary hypertension.

Authors:  Diana M Tabima; Sheila Frizzell; Mark T Gladwin
Journal:  Free Radic Biol Med       Date:  2012-03-06       Impact factor: 7.376

Review 7.  Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies.

Authors:  Stephen L Archer; E Kenneth Weir; Martin R Wilkins
Journal:  Circulation       Date:  2010-05-11       Impact factor: 29.690

8.  A novel regulatory mechanism of the bone morphogenetic protein (BMP) signaling pathway involving the carboxyl-terminal tail domain of BMP type II receptor.

Authors:  Mun Chun Chan; Peter H Nguyen; Brandi N Davis; Nobumichi Ohoka; Hidetoshi Hayashi; Keyong Du; Giorgio Lagna; Akiko Hata
Journal:  Mol Cell Biol       Date:  2007-06-18       Impact factor: 4.272

9.  Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia.

Authors:  R E Harrison; J A Flanagan; M Sankelo; S A Abdalla; J Rowell; R D Machado; C G Elliott; I M Robbins; H Olschewski; V McLaughlin; E Gruenig; F Kermeen; M Halme; A Räisänen-Sokolowski; T Laitinen; N W Morrell; R C Trembath
Journal:  J Med Genet       Date:  2003-12       Impact factor: 6.318

10.  Serum endostatin is a genetically determined predictor of survival in pulmonary arterial hypertension.

Authors:  Rachel Damico; Todd M Kolb; Lidenys Valera; Lan Wang; Traci Housten; Ryan J Tedford; David A Kass; Nicholas Rafaels; Li Gao; Kathleen C Barnes; Raymond L Benza; James L Rand; Rizwan Hamid; James E Loyd; Ivan M Robbins; Anna R Hemnes; Wendy K Chung; Eric D Austin; M Bradley Drummond; Stephen C Mathai; Paul M Hassoun
Journal:  Am J Respir Crit Care Med       Date:  2015-01-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.